Opendata, web and dolomites

LungCARD SIGNED

Blood test for clinical therapy guidance of non-small cell lung cancer patients

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 LungCARD project word cloud

Explore the words cloud of the LungCARD project. It provides you a very rough idea of what is the project "LungCARD" about.

mutation    lungcard    multiplex    tki    samples    fp7    cancers    75    frequencies    treatment    lung    tyrosine    poor    improvement    kinase    error    exchange    software    reporting    hospitals    capture    sick    multidisciplinary    tumour    medicine    afitinib    network    never    mutations    drug    inhibitor    lower    microfluidic    automatic    putting    detection    human    somatic    data    biopsy    ffpe    dna    mainly    personalised    pcr    gene    validation    alone    ngs    chemotherapy    30    clinical    decision    proven    global    too    20    technologies    benefit    uk    scientists    report    egfr    detect    demonstrated    sanger    receive    perform    weak    yield    ctcs    cell    extracted    fixed    integration    histological    blood    workflow    training    sequencing    worldwide    confirmation    analyser    paraffin    point    small    quality    pharmacogenomics    amplify    biopsies    free    cancer    circulating    cells    nsclc    patients    faster    laboratories    chip   

Project "LungCARD" data sheet

The following table provides information about the project.

Coordinator
STAB VIDA INVESTIGACAO E SERVICOS EM CIENCIAS BIOLOGICAS LDA 

Organization address
address: RUA DOS INVENTORES S/N EDIFICIO MADAN PARQUE SALAS 2.18 E 2.19
city: CAPARICA
postcode: 2825 182
website: www.stabvida.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Portugal [PT]
 Project website http://www.lungcardrise.eu
 Total cost 1˙039˙500 €
 EC max contribution 976˙500 € (94%)
 Programme 1. H2020-EU.1.3.3. (Stimulating innovation by means of cross-fertilisation of knowledge)
 Code Call H2020-MSCA-RISE-2016
 Funding Scheme MSCA-RISE
 Starting year 2017
 Duration (year-month-day) from 2017-01-01   to  2020-12-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    STAB VIDA INVESTIGACAO E SERVICOS EM CIENCIAS BIOLOGICAS LDA PT (CAPARICA) coordinator 450˙000.00
2    FCIENCIAS.ID - ASSOCIACAO PARA A INVESTIGACAO E DESENVOLVIMENTO DE CIENCIAS PT (LISBON) participant 180˙000.00
3    UNIVERSITY OF HULL UK (HULL) participant 180˙000.00
4    GENOLOGICA MEDICA SL ES (MALAGA) participant 85˙500.00
5    UNIWERSYTET JAGIELLONSKI PL (KRAKOW) participant 40˙500.00
6    GENETIKS SAGLIK HIZMETLERI TICARETLIMITED SIRKETI TR (ISTANBUL) participant 22˙500.00
7    INSTITUT ZA ONKOLOGIJU I RADIOLOGIJU SRBIJE RS (BELGRADE) participant 18˙000.00
8    FUNDACAO DA FACULDADE DE CIENCIAS DA UNIVERSIDADE DE LISBOA FP PT (LISBOA) participant 0.00
9    FEDERAL UNIVERSITY OF AGRICULTURE ABEOKUTA NG (ABEOKUTA) partner 0.00
10    Institut Pasteur Du Maroc MA (Casablanca) partner 0.00
11    MILLI ONKOLOGIYA MERKEZI AZ (BAKU) partner 0.00
12    PARSEQ LAB CO LTD RU (SAINT PETERSBURG) partner 0.00
13    RESPUBLIKA ONKOLOGIYA ILMIY MARKAZI UZ (TASKENT) partner 0.00
14    Sloan-Kettering Institute for Cancer Research CORPORATION US (New York) partner 0.00
15    UNIVERSIDAD SAN MARTIN DE PORRES ASOCIACION PE (LIMA) partner 0.00
16    UNIVERSITE HASSAN II DE CASABLANCA MA (CASABLANCA) partner 0.00
17    UNIVERSITY OF TECHNOLOGY SYDNEY AU (SYDNEY) partner 0.00

Map

 Project objective

Lung cancer is the most common cancer worldwide. NSCLC alone make up about 75% of all lung cancers and most hospitals currently test all NSCLC patients for EGFR mutations (pharmacogenomics) for treatment decision (personalised medicine) – i.e., patients with mutation(s) in EGFR gene should receive a EGFR-Tyrosine Kinase Inhibitor (TKI) drug (e.g. afitinib) treatment; while those that do not present mutations in such gene, should be treated with chemotherapy. Currently, the laboratories use PCR and Sanger sequencing technologies to perform the EGFR analysis from tumour biopsies - Fixed Paraffin Embedded (FFPE) samples. Still, some patients (e.g., 30% in UK) may never get histological confirmation because they are too sick to make a biopsy. Furthermore, the results obtained with current methods still present low quality, mainly due to poor quality/low yield of DNA extracted from FFPE samples. The FP7 LungCARD project (www.lungcard.eu) has developed and demonstrated a LungCARD system - an automatic system composed by microfluidic chip and chip analyser - that allows to capture circulating tumour cells (CTCs) from blood samples, amplify by multiplex PCR and detect EGFR mutations, including also a software for data analysis and report. Although this new blood test has proven to be faster, cost-effective and human error-free, the detection of somatic mutations in EGFR gene at frequencies lower than 20% is still a weak point. Therefore, the main project’s goal is to benefit from this technology, through the development, improvement, integration and validation of the LungCARD system with NGS workflow and development of a software for automatic reporting clinical results. However, LungCARD project aims to go further, by putting together a global and unique network of multidisciplinary scientists for exchange of knowledge and research training focused on non-small cell lung cancer.

 Deliverables

List of deliverables.
Report on worldwide research and clinical practices related to Lung cancer pharmacogenomics and therapy Documents, reports 2019-05-30 15:17:14
Mid-term report on outreach activities (including participation in international events, workshops, seminars and publications) Documents, reports 2019-05-14 14:48:17
Project Website Websites, patent fillings, videos etc. 2019-05-30 15:32:25

Take a look to the deliverables list in detail:  detailed list of LungCARD deliverables.

 Publications

year authors and title journal last update
List of publications.
2019 Radmila Jankovic1 , Helena J. Goncalves2 , Milena Cavic1 , Carla Clemente2 , Michael Lind3 , Alexis Murillo Carrasco4 , Selama Nadifi5 , Meriem Khyatti6 , Tumininu Adebambo7 , Dilshod Egamberdiev8 1 Institute for Oncology and Radiology of Serbia, Belgrade, Serbia; 2 StabVida, Caparica, Portugal; 3 University of HULL, UK; 4 Centro de Genética y Biología Molecular, Facultad de Medicina Humana, Universidad de San Martín de Porres, Lima, Peru; 5 Universite Hassan II de Casablanca, Morocco; 6 Institut Pasteur Du Maroc, Morocco; 7 Federal University of Agriculture, Nigeria; 8 National Cancer Center of Uzbekistan, Uzbekistan.
LungCARD - Report on worldwide research and clinical practices related to lung cancer
published pages: , ISSN: 1107-0625, DOI:
JBUON Open Access Journal aimed at the rapid diffusion of scientific knowledge in Oncology. 2019-05-14

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "LUNGCARD" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "LUNGCARD" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.3.)

RESEARCH (2018)

REmote SEnsing techniques for ARCHaeology

Read More  

IN TIME (2018)

IN-SITU INSTRUMENT FOR MARS AND EARTH DATING APPLICATIONS

Read More  

INSA (2020)

Integrated Nitrogen Studies in Africa

Read More